DrugPatentWatch Database Preview
Incyte Corp Company Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the competitive landscape for INCYTE CORP, and what generic alternatives to INCYTE CORP drugs are available?
INCYTE CORP has one approved drug.
There are eight US patents protecting INCYTE CORP drugs.
There are one hundred and sixty-nine patent family members on INCYTE CORP drugs in forty-three countries and twenty-five supplementary protection certificates in sixteen countries.
Summary for Incyte Corp
| International Patents: | 169 |
| US Patents: | 8 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Incyte Corp
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET;ORAL | 202192-005 | Nov 16, 2011 | RX | Yes | Yes | 7,598,257 | Start Trial | Y | Y | Start Trial | ||
| Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET;ORAL | 202192-005 | Nov 16, 2011 | RX | Yes | Yes | 10,016,429 | Start Trial | Start Trial | ||||
| Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET;ORAL | 202192-001 | Nov 16, 2011 | RX | Yes | No | Start Trial | Start Trial | |||||
| Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET;ORAL | 202192-004 | Nov 16, 2011 | RX | Yes | No | Start Trial | Start Trial | |||||
| Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET;ORAL | 202192-002 | Nov 16, 2011 | RX | Yes | No | 8,722,693 | Start Trial | Y | Y | Start Trial | ||
| Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET;ORAL | 202192-005 | Nov 16, 2011 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for INCYTE CORP drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg | ➤ Subscribe | 2015-12-17 |
International Patents for Incyte Corp Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Portugal | 2173752 | Start Trial |
| Poland | 2173752 | Start Trial |
| Croatia | P20170090 | Start Trial |
| Eurasian Patent Organization | 201691294 | Start Trial |
| Eurasian Patent Organization | 201200132 | Start Trial |
| Ukraine | 116187 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Incyte Corp Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1966202 | C01966202/01 | Switzerland | Start Trial | FORMER OWNER: INCYTE CORPORATION, US |
| 2455382 | PA2017012 | Lithuania | Start Trial | PRODUCT NAME: RUKSOLITINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/12/773/001-006 20150311 |
| 2455382 | 17C1013 | France | Start Trial | PRODUCT NAME: RUXOLITINIB OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/12/773/001-016 20150313 |
| 1966202 | CR 2013 00005 | Denmark | Start Trial | PRODUCT NAME: RUXOLITINIB, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER RUXOLITINIB PHOSFAT; REG. NO/DATE: EU/1/12/773/001-003 20120823 |
| 1966202 | 2013/004 | Ireland | Start Trial | PRODUCT NAME: RUXOLITINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THREOF; REGISTRATION NO/DATE: EU/1/12/773/001-003 20120823 |
| 1966202 | C300574 | Netherlands | Start Trial | PRODUCT NAME: RUXOLITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/12/773/001-003 20120823 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
